Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...

Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...

Skin condition flare-ups during the humid season are leading some individuals to avoid social events and celebrations.

The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...

Medical Channel Asia's ongoing eczema survey reveals how chronic itch drives withdrawal, emotional strain, and missed celebrations during a period ...

A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...

Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

While mild sunshine may tempt you to keep the same summer routine, dermatologists warn that winter requires a careful shift ...

Johnson & Johnson has discontinued a mid-stage trial of its experimental drug for moderate to severe atopic dermatitis after ...

Equip health professionals with resources to diagnose and treat conditions across all skin tones. Make mental health support ...

Discover how skin barrier damage leads to irritation and breakouts, emphasizing the importance of protection over excessive ...